Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
奥拉帕尼联合度伐利尤单抗（加或不加贝伐单抗）治疗既往未接受过PARP抑制剂治疗的铂敏感复发性卵巢癌：一项II期多队列研究
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-23-2249
Drew, Yvette; Kim, Jae-Weon; Penson, Richard T; O'Malley, David M; Parkinson, Christine; Roxburgh, Patricia; Plummer, Ruth; Im, Seock-Ah; Imbimbo, Martina; Ferguson, Michelle; Rosengarten, Ora; Steeghs, Neeltje; Kim, Min Hwan; Gal-Yam, Einav; Tsoref, Daliah; Kim, Jae-Hoon; You, Benoit; De Jonge, Maja; Lalisang, Roy; Gort, Eelke; Bastian, Sara; Meyer, Kassondra; Feeney, Laura; Baker, Nigel; Ah-See, Mei-Lin; Domchek, Susan M; Banerjee, Susana
